Manas AI's Siddhartha Mukherjee on AI’s evolution, drug discovery and India-China’s role | HTLS 2026
Source Entity
Latest News: Todays Latest News Headlines from India & World | Hindustan Times

Manas AI CEO Siddhartha Mukherjee stated at the 2026 Hindustan Times Leadership Summit that a universal cancer cure is unlikely due to the disease's complexity. He highlighted breakthroughs in KRAS-targeting drugs while cautioning against AI biases in medical research.
The Complexity of Cancer and the Limits of a Universal Cure
At the 2026 Hindustan Times Leadership Summit, Siddhartha Mukherjee, CEO of Manas AI, provided a sobering yet optimistic assessment of the current state of cancer research. Addressing the persistent question of whether a universal cure for cancer is on the horizon, Mukherjee emphasized that such a goal is unlikely in the foreseeable future. He underscored a fundamental biological reality: every cancer is distinct, possessing unique genetic and molecular profiles that dictate how it responds to various therapeutic interventions. This biological heterogeneity serves as the primary barrier to a 'one-size-fits-all' treatment.
Progress and Persistent Challenges in Oncology
While a universal cure remains elusive, Mukherjee acknowledged the substantial strides made in treating specific malignancies. Significant clinical progress has been documented in the management of breast cancer, leukaemias, and lymphomas, where targeted therapies and improved diagnostics have drastically altered patient outcomes. Conversely, he identified pancreatic cancer and various cancers affecting the stomach and intestinal tract as areas where medical science continues to face daunting challenges. These cancers often remain aggressive and difficult to treat, highlighting the uneven nature of oncological advancement.
The Role of Technological Breakthroughs
Despite these challenges, innovation continues to drive the field forward. Mukherjee pointed to the development of a KRAS-targeting drug as a significant breakthrough, noting that the research journey for this specific therapeutic target spanned approximately a decade. This development exemplifies the rigorous and time-intensive nature of drug discovery. By leveraging advancements in immunotherapy, genetic sequencing, and artificial intelligence, researchers are slowly unraveling the mechanisms of previously intractable diseases, even if these solutions are highly specific rather than universal.
AI Evolution and the Human-Machine Interface
Beyond oncology, Mukherjee analyzed the broader evolution of artificial intelligence, tracing its trajectory back to the landmark 1997 victory of IBM’s Deep Blue over Garry Kasparov. He distinguished between symbolic AI and neural learning, noting that human intelligence relies heavily on neural processes supplemented by symbolic reasoning. He argued that AI holds transformative potential for medicine, provided it is developed with a clear understanding of its underlying learning systems.
Addressing Bias and the Future of Clinical Trials
As AI becomes more integrated into healthcare, Mukherjee raised critical concerns regarding algorithmic bias—a concept he termed 'Bibo' or 'bias in, bias out.' He emphasized that without careful oversight, existing human biases can be amplified by machine learning models. To mitigate these risks and accelerate medical innovation, he suggested that synthetic controls using historical or simulated data could complement traditional, randomized, blinded clinical trials. By refining how we validate these technologies, the medical community can better navigate the powerful yet potentially dangerous rapid rise of AI in clinical practice.
Conclusion
The synthesis of Mukherjee's insights suggests a future defined by precision medicine rather than a singular, miraculous cure. While the integration of AI into drug discovery and clinical trials offers a promising pathway for addressing complex cancers, the field must remain vigilant against technical and ethical pitfalls. The path forward involves a nuanced understanding of biological diversity and a commitment to rigorous, unbiased data practices.
Verification Required?